Boston Scientific Corporation vs Kroger Co — how do they compare? Boston Scientific Corporation trades at $51.15 (market cap $71.46B), while Kroger Co trades at $56.18 (market cap $34.60B). The key difference: Boston Scientific Corporation is far larger — about 2.1× Kroger Co's market cap, and Kroger Co pays a 2.55% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | KR | |
|---|---|---|
Market Cap | $71.46B | $34.60B |
Sector | Health | Consumer Staples |
52-Week High | $108.14 | $75.60 |
52-Week Low | $42.63 | $55.53 |
Enterprise Value | $83.55B | $54.70B |
Dividend Yield | — | 2.55% |
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $49.31, up slightly by 0.02% on the day, with a bullish technical signal from moving averages despite overbought RSI readings near 77–83. The company reported strong Q2 2026 results, beating EPS estimates with $0.86 actual versus $0.835 expected, and revenue growth of 7.5%. Fundamentals show robust profitability with a net income margin of 17.5% and ROE of 15.52%, though 2026 guidance was trimmed due to WATCHMAN and electrophysiology segment pressures.
BSX presents a compelling investment case with 86% analyst buy ratings and a $67.21 consensus price target implying 36% upside. Key risks include competitive pressures in medical devices and execution on cost savings. The stock's valuation at a P/E of 19.96 appears reasonable given earnings growth, but investors must weigh near-term headwinds against long-term innovation catalysts.
Kroger (KR) trades at $56.73, down 1.03% with bearish technical signals from moving averages. The company maintains stable revenue around $147B with recent earnings showing mixed results - beating estimates in Q3 and Q4 2025 but missing in Q1 2026. Kroger demonstrates strong cash flow generation with $5.8B from operations in 2025 and pays consistent dividends, while expanding digital services and AI shopping assistance.
Kroger presents a defensive investment opportunity with 2.7% dividend yield and analyst consensus target of $68.63 (21% upside). However, rising debt levels and competitive pressures in grocery retail pose risks. The stock offers value with P/S of 0.25x but trades at premium P/E of 33x, requiring earnings acceleration to justify valuation.
Trailing returns across standard periods
Latest headlines on both assets
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →